Guggenheim Capital LLC Acadia Pharmaceuticals Inc Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 55,811 shares of ACAD stock, worth $952,693. This represents 0.01% of its overall portfolio holdings.

Number of Shares

55,811

Previous 56,917 1.94%

Holding current value

$952,693

Previous $924,000 7.14%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$15.14 - $19.14 $16,744 - $21,168	-1,106 Reduced 1.94%	55,811 $858,000
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $105,863 - $133,379	7,241 Added 14.58%	56,917 $924,000
Q1 2024 May 14, 2024	BUY	$17.79 - $30.86 $26,987 - $46,814	1,517 Added 3.15%	49,676 $918,000
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $65,623 - $100,329	3,158 Added 7.02%	48,159 $1.51 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $59,081 - $94,887	-2,835 Reduced 5.93%	45,001 $937,000
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $55,126 - $79,438	-3,097 Reduced 6.08%	47,836 $1.15 Million
Q1 2023 May 10, 2023	BUY	$16.32 - $20.92 $831,226 - $1.07 Million	50,933 New	50,933 $958,000
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $139,896 - $292,696	-10,753 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $32,101 - $42,157	1,533 Added 16.63%	10,753 $261,000
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $1.43 Million - $2.3 Million	-85,059 Reduced 90.22%	9,220 $216,000
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $231,429 - $363,276	14,666 Added 18.42%	94,279 $1.57 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $27.42 $26,771 - $37,839	1,380 Added 1.76%	79,613 $1.94 Million
Q1 2021 May 13, 2021	BUY	$25.02 - $54.99 $575,359 - $1.26 Million	22,996 Added 41.63%	78,233 $2.02 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $944,289 - $1.31 Million	-23,009 Reduced 29.41%	55,237 $2.95 Million
Q3 2020 Nov 13, 2020	SELL	$36.42 - $57.0 $389,876 - $610,185	-10,705 Reduced 12.03%	78,246 $3.23 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $293,743 - $394,525	7,482 Added 9.18%	88,951 $4.31 Million
Q1 2020 Jun 02, 2020	SELL	$31.65 - $46.87 $566,598 - $839,066	-17,902 Reduced 18.02%	81,469 $3.44 Million
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $558,249 - $792,433	15,417 Added 18.36%	99,371 $4.25 Million
Q3 2019 Nov 14, 2019	SELL	$22.22 - $44.01 $670,044 - $1.33 Million	-30,155 Reduced 26.43%	83,954 $3.02 Million
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $356,749 - $430,179	-15,298 Reduced 11.82%	114,109 $3.05 Million
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $529,761 - $897,023	-32,762 Reduced 20.2%	129,407 $3.48 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $53,914 - $86,293	-3,765 Reduced 2.27%	162,169 $2.62 Million
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $95,952 - $160,608	-7,364 Reduced 4.25%	165,934 $3.45 Million
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $282,547 - $418,852	18,749 Added 12.13%	173,298 $2.65 Million
Q1 2018 May 15, 2018	BUY	$22.47 - $32.33 $189,579 - $272,768	8,437 Added 5.77%	154,549 $3.47 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $433,492 - $632,150	-16,151 Reduced 9.95%	146,112 $4.4 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $4.79 Million - $6.23 Million	162,263	162,263 $6.11 Million

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Acadia Pharmaceuticals Inc Transaction History